Citius Oncology's LYMPHIR Gaining 83% Formulary Adoption, Covered by 135 Health Plans
Citius Oncology's LYMPHIR secured formulary adoption in 83% of target US oncology centers and coverage with 135 health plans representing 80% of covered lives, generating repeat orders and community infusion starts. Investigator-led trials in diffuse large B-cell lymphoma and solid tumors yielded positive topline results, supporting LYMPHIR's immunotherapy combination potential.
1. Early U.S. Launch Metrics
Since its December 2025 launch, LYMPHIR has seen sequential order growth with repeat orders from target oncology centers, achieving formulary adoption in 83% of accounts and securing reimbursement across 135 health plans representing 80% of covered lives without denials or authorization barriers.
2. Field Deployment and Market Expansion
Citius Oncology is onboarding a dedicated field team this quarter to support community infusion center penetration, roll out medical education and digital campaigns, and has executed distribution agreements across Europe and the Middle East to prepare for international expansion.
3. Investigator-Led Clinical Studies
Investigator-sponsored trials at the University of Minnesota in relapsed/refractory diffuse large B-cell lymphoma and at UPMC in combination with pembrolizumab for solid tumors reported positive topline data, underpinning LYMPHIR’s potential in immunotherapy combination regimens.